Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Study Overview: This research aims to find out how well a new drug called COMP360 works for adults with treatment-resistant depression (TRD). TRD means you've tried at least two depression medicines that didn't help. COMP360 will be given in two different doses to see which works best.

Study Design: This is a phase III trial, which means it’s one of the last steps before a new treatment can be approved. It’s double-blind, so neither you nor the researchers will know which dose you’re getting. The study will last up to 16 weeks. During this time, you’ll have a screening period (3-10 weeks) and a follow-up (6 weeks) after getting the treatment.

• You must be 18 or older and have TRD.
• The study involves taking COMP360 with psychological support.
• Some people can’t join, like those with certain mental health conditions.

If you join, you’ll be helping find better treatments for depression but remember there are always risks, like side effects or the treatment not working for you.